ClinicalTrials.Veeva

Menu

Depakote ER in Borderline Personality Disorder

University of Minnesota (UMN) logo

University of Minnesota (UMN)

Status

Completed

Conditions

Borderline Personality Disorder

Treatments

Drug: Depakote ER

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT00222482
0306M49703
M009946

Details and patient eligibility

About

This study examines the effect of Depakote ER versus placebo in a randomized trial of borderline personality disorder. Patients all participate in DBT therapy and those who are not responsive are assigned to either Depakote ER or placebo for up to 12 weeks. Borderline Personality Symtoms are measured and side-effects are assessed.

Sex

All

Ages

21 to 55 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:Male or female patients with the diagnosis of borderline personality disorder between the ages of 21 adn 55 years old. Must be in good physical health -

Exclusion Criteria:Major psychiatric illness on Axis I - schizophrenia or bipolar disorder. May not have current MDD. May not be dependent on illicit substances or alcohol.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems